Background: Arterial (ATE) and venous thromboembolism (VTE) are common complications of cancer, but their impact on cancer symptom assessment and symptom burden is unknown. We sought to measure and compare the uptake of routine symptom assessment at Regional Cancer Centres (RCC) and to examine symptom burden progression in patients with newly diagnosed cancer and ATE or VTE versus matched controls.

Methods: We conducted a population-based, retrospective matched cohort study in Ontario, Canada including adults (≥18 years) with a new cancer diagnosis (2007–2021). In two separate cohorts, patients with ATE or VTE within 6 months of diagnosis were matched to controls (1:5) based on age, sex, and cancer site. Basal/squamous cell carcinomas were excluded. The index date was the date of cancer diagnosis plus 6 months. Follow-up continued for 1 year or until death, non-residence in Ontario, or study end. Exposures were ATE or VTE, identified using validated ICD-9 or ICD-10 codes from hospitalizations or emergency department visits. The primary outcome was completion of the Edmonton Symptom Assessment System (ESAS), a validated tool that assesses self-reported symptoms of cancer. We calculated ESAS rates per 100 person-days compared them using generalized linear models. Relative rates (RR) were estimated via Andersen Gill models adjusted for imbalanced baseline characteristics. We then implemented a Markov multistate model to examine symptom severity progression over time for five symptoms (pain, anxiety, depression, lack of wellbeing, shortness of breath) by classifying patients as: none (ESAS score=0), mild/moderate (ESAS score=1–6), severe (ESAS score=7–10), or death.

Results: The ATE cohort included 7,039 patients with ATE and 35,195 controls (mean age 70 years, 36% female). The most common cancer sites were lung (19.0%), hematologic (18.7%), and colorectal (14.0%). Patients with ATE had a lower ESAS rate (0.31 vs. 0.38 per 100 person-days; RR 0.81) despite a higher RCC visit rate (2.11 vs. 1.96 per 100 person-days, relative rate [RR] 1.08). ATE (RR 0.89 95%CI 0.85-0.94) and high comorbidity burden (RR 0.74 95%CI 0.66-0.83) were associated with a lower ESAS rate, while systemic therapy increased the rate (RR 3.34 95%CI 3.22-3.46). Among 3,218 patients with ATE (21,591 assessments) and 18,060 controls (135,201 assessments), baseline states were similar between groups. However, patients with ATE had a higher odds of worsening severity in all states (none, mild/moderate, severe) and across all symptoms compared to controls.

The VTE cohort included 3,002 patients with VTE and 15,010 controls (mean age 64 years, 54% female). The most common cancer sites were lung (19.1%), hematologic (15.3%), and colorectal (12.5%). Patients with VTE had a higher ESAS rate (0.62 vs. 0.43 per 100 person-days; RR 1.44) and a higher RCC visit rate (3.49 vs. 1.99 per 100 person-days; RR 1.75). Systemic therapy (RR 2.68 95%CI 2.53-2.84), radiation (RR 1.07 95%CI 1.02-1.13), and advanced stage (stage II RR 1.30 95%CI 1.20-1.41, stage III RR 1.67 95%CI 1.53-1.92, stage IV RR 2.39 95%CI 2.19-2.60) were associated with higher ESAS rates. Among 1,744 patients with VTE (15,016 assessments) and 8,390 controls (66,836 assessments), baseline states were generally worse for VTE patients, specifically for pain, lack of wellbeing, and shortness of breath. Patients with VTE had a higher odds of worsening severity in all states and across all symptoms compared to controls.

Conclusion: In patients with newly diagnosed cancer, ATE was associated with a lower ESAS rate despite a higher RCC visit rate, while VTE was associated with a higher ESAS rate compared to controls. Patients with ATE or VTE had a higher odds of worsening symptom severity compared to controls, highlighting the need to improve symptom monitoring and management in patients with thrombotic complications of cancer. Further studies should explore contributors to lower assessment rates in patients with ATE and to optimize assessment strategies.

This content is only available as a PDF.
2025
Sign in via your Institution